Similar Papers

Paper Title
Journal
Date
Author
Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC) (165)
Jerold Loh ... David Tan
Gynecologic Oncology | VOL. 166
Jerold Loh, et. al.Jerold Loh ... David Tan
01 Aug 2022
The predictive role of PD-L1 expression and CD8 + TIL levels in determining the neoadjuvant chemotherapy response in advanced ovarian cancer
T Aliyeva ... A Usubutun
Journal of Ovarian Research | VOL. 17
T Aliyeva, et. al.T Aliyeva ... A Usubutun
23 Nov 2024
Chemotherapy response score as a prognostic tool in advanced-stage endometrial cancer patients treated with neoadjuvant chemotherapy.
Ina Jani ... Isabel Lazo
Journal of Clinical Oncology | VOL. 38
Ina Jani, et. al.Ina Jani ... Isabel Lazo
20 May 2020
Prognostic value of complete metabolic response on ¹⁸F-FDG-PET/CT after three cycles of neoadjuvant chemotherapy in advanced high-grade serous ovarian cancer.
Young Shin Chung ... Won Jun Kang
Journal of gynecologic oncology | VOL. 33
Young Shin Chung, et. al.Young Shin Chung ... Won Jun Kang
01 Jan 2021
View more papers

More From: Gynecologic Oncology

Paper Title
Journal
Date
Author
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
Aine Clements ... Angeles Alvarez Secord
Gynecologic oncology | VOL. 193
Aine Clements, et. al.Aine Clements ... Angeles Alvarez Secord
23 Jan 2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
David M O'Malley ... Michele Maio
Gynecologic oncology | VOL. 193
David M O'Malley, et. al.David M O'Malley ... Michele Maio
22 Jan 2025
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
Michael D Toboni ... Nathaniel Jones
Gynecologic oncology | VOL. 193
Michael D Toboni, et. al.Michael D Toboni ... Nathaniel Jones
20 Jan 2025
Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ.
M Schaafsma ... N.E Van Trommel
Gynecologic oncology | VOL. 193
M Schaafsma, et. al.M Schaafsma ... N.E Van Trommel
17 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.